Hope for lung cancer patients: new combo therapy targets relapsed stage III disease

NCT ID NCT05568212

Recruiting now Disease control Sponsor: Fondazione Ricerca Traslazionale Source: ClinicalTrials.gov ↗

First seen Dec 11, 2025 · Last updated May 05, 2026 · Updated 19 times

Summary

This study tests whether adding immune drugs (durvalumab and olaparib) to standard chemotherapy can help people with stage III non-small-cell lung cancer whose cancer has returned after initial treatment. About 176 adults will be split into groups based on when their cancer progressed, and they will receive either standard chemo alone or chemo plus one or two immune drugs. The goal is to see if the combinations help people live longer without their cancer growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
RECRUITING

Roma, RM, 00144, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL-CELL LUNG CANCER PATIENTS NON-SMALL-CELL LUNG CANCER PATIENTS